A truncated and thus noncyclic tumor-homing peptide tPlP-1 shows a promising possibility for targeting therapeutic and diagnostic agents to breast cancer cells, as it binds to both NRP1 and NRP2 and improves extravasation of co-injected nanoparticles into the tumor tissue [394]. Here, NRP2 is linked to breast carcinoma.